简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2026-10-23 15:20 SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age
2026-10-23 14:48 AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
2026-10-23 14:12 Future Health and Bridge for Billions to Launch Programme Strengthening Health Entrepreneurship in Emerging Markets
2026-10-22 14:29 Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
2026-10-22 11:42 Global Network for the Advancement of Metabolic Psychiatry (MetPsy) Launches with $20 Million Investment in Clinical Care, Education and Research at McLean Hospital
2026-10-22 11:17 Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
2026-10-21 15:16 Unimed Appoints Sune Svenningsen as Chief Executive Officer
2026-10-21 15:05 AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
2026-10-21 14:27 Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility
2026-10-21 14:10 Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge
2026-10-20 11:25 Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 2026
2026-10-20 11:20 Hologic Signs Definitive Agreement to Acquire Reveal Genomics
2026-10-20 11:12 BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
2026-10-19 17:44 First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
2026-10-17 10:10 Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody Conjugate
2026-10-16 16:24 Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
2026-10-16 16:05 New Study Brings Ketogenic Therapy for Bipolar Disorder Directly to Rural Alabama Homes
2026-10-16 14:23 Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application
2026-10-16 14:14 CTIBIOTECH™ Announces Strategic Partnership and MOU With Beijing Vital River to Advance Preclinical Biomedical Innovation in China
2026-10-15 14:32 PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Business Wire Weibo

Press Releases

Latest Releases